Новости

  • Proposed dividend for Krka shareholders 17.2% higher than last year

    At yesterday’s regular Supervisory Board meeting, the Krka Supervisory Board and Management Board drew up a proposal that Krka pays its shareholders a dividend of €6.60 gross per share, which is an increase of 17.2% on last year’s dividend.

  • Дабиксом – первый дженерик дабигатрана в России

    Компания КРКА является одним из ведущих в мире производителей качественных  дженериковых препаратов. Препараты компании КРКА вносят весомый вклад в поддержание общественного здоровья.

  • Асиглия - новинка КРКА для лечения сахарного диабета 2 типа.

    С 4 квартала 2022 года ассортимент КРКА в России дополнен новым терапевтическим направлением – препаратами для лечения диабета.

  • Be the change you want to see in the world!

    We observe World Water Day on 22 March annually, and highlight another theme every time to draw attention of the general public to relevant and pressing issues surrounding water. Accompanied by various events and activities in the world, this World Water Day is about solving the water and sanitation crisis.

  • Krka Releases 2022 Unaudited Financial Statements

    Krka released the 2022 unaudited financial statements of the Krka Group and the controlling company Krka, d. d., Novo mesto today. The report was published on the Ljubljana Stock Exchange website after being discussed by the company’s Supervisory Board at their meeting yesterday. The Krka Group revenue in 2022 totalled €1,717.5 million, up 10% on 2021, the highest since incorporation. The Krka Group’s unaudited net profit was €363.7 million, an increase by €55.5 million year-over-year, or 18%, i.e. also the highest so far. The 2022 Annual Report is being released on Thursday, 13 April 2023.